Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027
Summary
The Glioblastoma Multiforme (GBM) market is expected to grow from $662.0m in 2017 to $1.4bn in 2027 across the eight major markets (8MM) ( US, France, Germany, Italy, Spain, UK, Japan, and urban China) representing a compound annual growth rate (CAGR) of 7.5.
Glioblastoma Multiforme (GBM), otherwise known as Grade IV astrocytoma, is the most aggressive form of brain cancer and characterized as a disease with one of the highest unmet needs in oncology, with patients having a median overall survival (OS) between one and two years. Although Glioblastoma Multiforme (GBM) is a rare disease, the high level of unmet need in this market creates ample opportunities for players with effective therapies.
However, there is a significant lack of effective therapies in the current market due to the inability of drugs to penetrate the blood-brain barrier (BBB). The only targeted agent approved for recurrent Glioblastoma Multiforme (GBM) patients is Roche's Avastin (bevacizumab), approved in the US in 2008 and Japan in 2013 and used off-label in the 5EU and China. Otherwise, generic temozolomide in combination with radiotherapy makes up the majority of the GBM market and is considered the standard of care across the 8MM.
Since Glioblastoma Multiforme (GBM) patients have no effective treatment options and low survival expectancy, there is the potential for high uptake in the market if an agent is capable of increasing survival or quality of life. Although progress has been made, survival rates are still dismal. Therapies that can prolong the overall survival (OS) of patient's refractory to Avastin are the greatest unmet need in the Glioblastoma Multiforme (GBM) space; fulfilling this need is a safe route to regulatory approval and commercial success.
Like other orphan indications with high levels of unmet need, it is clear that effective therapies for Glioblastoma Multiforme (GBM) can demand premium pricing. Although Glioblastoma Multiforme (GBM) affects a relatively small number of patients, there are seven drugs in the late stages of development. These include Opdivo, DCVax-L, and depatuxizumab mafodotin, which have shown promising efficacy in early-stage trials. The level of unmet need for Glioblastoma Multiforme (GBM) patients is exceedingly high, which will facilitate the adoption of these new drug candidates.
The latest report "Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027", states that a drive to address the high level of unmet needs will be hindered by difficulties in clinical development, leading to only modest growth in the Glioblastoma Multiforme (GBM) market.
Scope
Reasons to buy
The report will enable you to -
Summary
The Glioblastoma Multiforme (GBM) market is expected to grow from $662.0m in 2017 to $1.4bn in 2027 across the eight major markets (8MM) ( US, France, Germany, Italy, Spain, UK, Japan, and urban China) representing a compound annual growth rate (CAGR) of 7.5.
Glioblastoma Multiforme (GBM), otherwise known as Grade IV astrocytoma, is the most aggressive form of brain cancer and characterized as a disease with one of the highest unmet needs in oncology, with patients having a median overall survival (OS) between one and two years. Although Glioblastoma Multiforme (GBM) is a rare disease, the high level of unmet need in this market creates ample opportunities for players with effective therapies.
However, there is a significant lack of effective therapies in the current market due to the inability of drugs to penetrate the blood-brain barrier (BBB). The only targeted agent approved for recurrent Glioblastoma Multiforme (GBM) patients is Roche's Avastin (bevacizumab), approved in the US in 2008 and Japan in 2013 and used off-label in the 5EU and China. Otherwise, generic temozolomide in combination with radiotherapy makes up the majority of the GBM market and is considered the standard of care across the 8MM.
Since Glioblastoma Multiforme (GBM) patients have no effective treatment options and low survival expectancy, there is the potential for high uptake in the market if an agent is capable of increasing survival or quality of life. Although progress has been made, survival rates are still dismal. Therapies that can prolong the overall survival (OS) of patient's refractory to Avastin are the greatest unmet need in the Glioblastoma Multiforme (GBM) space; fulfilling this need is a safe route to regulatory approval and commercial success.
Like other orphan indications with high levels of unmet need, it is clear that effective therapies for Glioblastoma Multiforme (GBM) can demand premium pricing. Although Glioblastoma Multiforme (GBM) affects a relatively small number of patients, there are seven drugs in the late stages of development. These include Opdivo, DCVax-L, and depatuxizumab mafodotin, which have shown promising efficacy in early-stage trials. The level of unmet need for Glioblastoma Multiforme (GBM) patients is exceedingly high, which will facilitate the adoption of these new drug candidates.
The latest report "Glioblastoma Multiforme (GBM): Opportunity Analysis and Forecasts to 2027", states that a drive to address the high level of unmet needs will be hindered by difficulties in clinical development, leading to only modest growth in the Glioblastoma Multiforme (GBM) market.
Scope
- Overview of GBM, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and disease management.
- Annualized GBM therapeutics market revenue, cost of therapy per patient, and treatment usage patterns in eight geographic regions, forecast from 2017 to 2027.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping and implications for the GBM therapeutics market.
- Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for GBM. The most promising candidates in late-stage development are profiled.
- Analysis of the current and future market competition in the global GBM market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global GBM market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global GBM market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
Table of Contents
1.1 List of Tables1.2 List of Figures
2 Executive Summary
2.1 New Entrants Will Drive Modest Growth Across the 8MM from 2017 to 2027
2.2 Launch of Immunotherapies and Biomarker-Driven Therapies Will Lead to Change in the GBM Landscape
2.3 High Unmet Needs Exist in the GBM Market, Especially in Patients Refractory to Avastin
2.4 Pipeline Agents Will Offer Incremental Improvements over Current Therapies
2.5 What Do Physicians Think?
3 Introduction
3.1 Catalyst
3.2 Related Reports
3.3 Upcoming Related Reports
4 Disease Overview
4.1 Etiology and Pathophysiology
4.1.1 Etiology
4.1.2 Pathophysiology
4.2 Symptoms
5 Epidemiology
5.1 Disease Background
5.2 Risk Factors and Comorbidities
5.3 Global and Historical Trends
5.4 Forecast Methodology
5.4.1 Sources
5.4.2 Forecast Assumptions and Methods
5.5 Epidemiological Forecast for Brain Cancer (2017-2027)
5.5.1 Diagnosed Incident Cases of Brain Cancer
5.5.2 Age-Specific Diagnosed Incident Cases of Brain Cancer
5.5.3 Sex-Specific Diagnosed Incident Cases of Brain Cancer
5.5.4 Five-Year Diagnosed Prevalent Cases of Brain Cancer
5.5.5 Diagnosed Incident Cases of Brain Cancer by Type
5.6 Discussion
5.6.1 Epidemiological Forecast Insight
5.6.2 Limitations of the Analysis
5.6.3 Strengths of the Analysis
6 Current Treatment Options
6.1 Overview
7 Unmet Needs Assessment and Opportunity Analysis
7.1 Overview
7.2 Identification of New Treatment Options for Patients with rGBM Refractory to Avastin
7.3 More Efficacious Treatment for Patients with MGMT-Unmethylated Promoters
7.4 Criteria to Evaluate Tumor Response
7.5 Reduced Use of Steroids in GBM Patients
7.6 Identification of Biomarkers Predictive of Therapeutic Efficacy
7.7 More Agents Required for Unresectable GBM
8 R&D Strategies
8.1 Overview
8.1.1 Assessment of Immunotherapy Efficacy in GBM
8.1.2 Increased Use of Biomarkers to Better Predict Treatment Efficacy
8.1.3 Moving Towards Less-Cumbersome Cancer Vaccines to Facilitate Approval
8.1.4 Local Administration of Therapeutics During Surgery
8.1.5 Revisiting Older Strategies and Developing Modifications to Increase Effectiveness
8.2 Clinical Trial Design
8.2.1 Clinical Endpoints
8.2.2 Comparator Arms
8.2.3 Combination Approach
9 Pipeline Assessment
9.1 Overview
9.2 Recent Drug Failures in GBM
9.3 Innovative Early-Stage Approaches
9.3.1 Checkpoint Modulator Combinations
9.3.2 Vaccines and T-cell Therapies
9.3.3 Small Molecules
10 Pipeline Valuation Analysis
10.1 Clinical Benchmark of Key Pipeline Drugs
10.2 Commercial Benchmark of Key Pipeline Drugs
10.3 Competitive Assessment
10.4 Top Line 10-Year Forecast
10.4.1 US
10.4.2 5EU
10.4.3 Japan
10.4.4 China (Urban)
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.4.1 Diagnosed GBM Patients
11.4.2 Percent Drug-Treated Patients
11.4.3 Drugs Included in Each Therapeutic Class
11.4.4 Launch and Patent Expiry Dates
11.4.5 General Pricing Assumptions
11.4.6 General Forecast Assumptions
11.4.7 Individual Drug Assumptions
11.4.8 Generic and Biosimilar Erosion
11.4.9 Pricing of Pipeline Agents
11.5 Physicians and Specialists Included in this Study
11.5.1 High-Prescribing Physician Survey
11.6 About the Authors
11.6.1 Author
11.6.2 Epidemiologist
11.6.3 Therapy Director
11.6.4 Global Director of Therapy Analysis and Epidemiology
11.6.5 Global Head of Healthcare
11.7 About the Publisher
11.8 Contact Us
11.9 Disclaimer
1.1 List of Tables
Table 1: Glioblastoma: Key Metrics in Eight Major Pharmaceutical Markets, 2017-2027
Table 2: Symptoms of Glioblastoma
Table 3: Description of Brain Cancer Types
Table 4: Leading Treatments for GBM
Table 5: Treatment Guidelines for GBM
Table 6: Design of Current Phase III Trials in GBM
Table 7: Glioblastoma - Late Stage Pipeline, 2018
Table 8: GBM - Recent late-stage drug discontinuations
Table 9: Innovative Early-Stage Approaches for GBM, 2018
Table 10 Clinical Benchmark of Key Marketed and Pipeline Drugs - Newly Diagnosed GBM
Table 11: Clinical Benchmark of Key Marketed and Pipeline Drugs - Recurrent GBM
Table 12: Commercial Benchmark of Key Marketed and Pipeline Drugs - Newly Diagnosed GBM
Table 13: Commercial Benchmark of Key Marketed and Pipeline Drugs - Recurrent GBM
Table 14: Key Events Impacting Sales for Glioblastoma, 2017-2027
Table 15: GBM Market - Drivers and Barriers, 2017-2027
Table 16: Key Launch Dates in the GBM Market, 20172027
Table 17: Key Patent Expiries in the GBM Market, 2017-2027
Table 18: Average Body Weight and Surface Area Across the 8MM
Table 19: High-Prescribing Physicians (non-KOLs) Surveyed, By Country
1.2 List of Figures
Figure 1: GBM Sales by Country, 2017-2027
Figure 2: Competitive Assessment of Late-Stage Pipeline Agents in Newly Diagnosed GBM, 2017-2027
Figure 3: Competitive Assessment of Late-Stage Pipeline Agents in Recurrent GBM, 2017-2027
Figure 4: 8MM, Age-Standardized Diagnosed Incidence of Brain Cancer, Men and Women, All Ages, 2017
Figure 5: Sources Used and Not Used to Forecast Diagnosed Incident Cases of Brain Cancer
Figure 6: Sources Used and Not Used to Forecast the Five-Year Diagnosed Prevalent Cases of Brain Cancer
Figure 7: Sources Used to Forecast Diagnosed Incident Cases of Brain Cancer by Type
Figure 8: 8MM, Diagnosed Incident Cases of Brain Cancer, Men and Women, All Ages, 2017
Figure 9: 8MM, Age-Specific Diagnosed Incident Cases of Brain Cancer, Men and Women, 2017, N
Figure 10: 8MM, Sex-Specific Diagnosed Incident Cases of Brain Cancer, Men and Women, All Ages, 2017
Figure 11: 8MM, Five-Year Diagnosed Prevalent Cases of Brain Cancer, Men and Women, All Ages, 2017
Figure 12: 8MM, Diagnosed Incident Cases of Brain Cancer by Type, Men and Women, All Ages, 2017, N
Figure 13: Unmet Needs and Opportunities in GBM
Figure 14: Overview of the Development Pipeline in GBM
Figure 15: Late-Stage Therapies for GBM, 2018
Figure 16: Competitive Assessment of Late-Stage Pipeline Agents in Newly Diagnosed GBM, 2017-2027
Figure 17: Competitive Assessment of Late-Stage Pipeline Agents in Recurrent GBM, 2017-2027
Figure 18: GBM Sales by Country, 2017-2027
Figure 19: GBM Sales by Therapeutic Class, 2017-2027
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Roche
- Merck
- Bristol-Myers Squibb
- AbbVie
- Celgene.
- Eisai
- Arbor Pharmaceutical
- Northwest Biotherapeutics
- Chugai Pharmaceutical
- Ono Pharmaceutical
- Tocagen
- DelMar Pharmaceuticals
- Diffusion Pharmaceuticals
- DNAtrix
